

**ABSTRACT OF THE DISCLOSURE**

This application describes a method of preparing stabilized sustained release tablets containing bupropion hydrochloride and carboxyvinyl polymers, in which the composition contains, at least about 90% w/w of undegraded Bupropion hydrochloride after storage for two weeks at 55°C and for three months at 40°C and 75% relative humidity.